Drugs / Benzocaine
Benzocaine
also known as
AR01 · Aezodent · Americaine · Anaesthesin · Anthisan plus · Baby anbesol · Benzocaina · Benzocaine Spray · +23 more
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06272903 | Apr → Dec 2024 | — | Mohammed Bin Rashid University of Medicine and Health Sciences | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01054547 | Sep → Dec 2006 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT07031206 | Jul 2025 → May 2026 overdue | anxiety | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03233737 | Jun 2017 → Feb 2018 | — | Cetylite Industries | Completed | No outcome recorded |
| Phase 2 | NCT02908620 | Dec 2016 → Apr 2017 | — | Cetylite Industries | Completed | Missed primary |
| Phase 2 | NCT02092454 | Sep 2013 → Mar 2014 | otitis media | Otic Therapy, LLC | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07242157 | Apr → Jun 2024 | — | TC Erciyes University | Completed | No outcome recorded |
| Phase 3 | NCT05788497 | Mar 2023 → Jan 2024 | hemorrhoid | Faes Farma, S.A. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04859738 | Mar → Jul 2020 | — | TC Erciyes University | Completed | No outcome recorded |
| Phase 3 | NCT03432923 | Feb → Apr 2018 | pharyngitis | McNeil AB | Completed | No outcome recorded |
| Phase 3 | NCT03116737 | Jan → Jul 2017 | otitis media | Lachlan Pharma Holdings | Completed | No outcome recorded |
| Phase 3 | NCT01429701 | May → Jun 2012 | dermatitis | EMS | Completed | No outcome recorded |
| Phase 3 | NCT00148499 | Oct 2005 → Jun 2006 | acute pharyngitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 45 trials · 1 missed | ||||||
| Phase 4 | NCT07401134 | Feb 2026 → Jan 2027 expected | vulvodynia | University of Miami | Recruiting | No outcome recorded |
| Phase 4 | NCT07198022 | Sep 2025 → Jan 2026 | — | Ondokuz Mayıs University | Completed | No outcome recorded |
| Phase 4 | NCT06951191 | Jun 2025 → Apr 2026 | — | University of Missouri-Columbia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06569537 | Oct 2024 → Dec 2025 | — | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01925469 | Dec 2011 → Apr 2012 | — | University of Pennsylvania | Completed | Missed primary |
| Phase not applicable3 trials | ||||||
| — | NCT07682181 | Jun → Dec 2026 expected | — | Government Dental College and Hospital, India | Not yet recruiting | No outcome recorded |
| — | NCT02379221 | Sep 2014 → Mar 2016 | — | David Grant U.S. Air Force Medical Center | Completed | No outcome recorded |
| — | NCT01842373 | Jul → Sep 2013 | — | Milton S. Hershey Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy29 trials | ||||||
| Phase 0 | NCT06804616 Comparator | Nov → Dec 2024 | — | University of Lahore | Completed | No outcome recorded |
| Phase 0 | NCT05060913 Comparator | Nov 2021 → Mar 2022 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02537314 Comparator | Sep 2015 → Dec 2022 | obesity disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01694004 Background | Nov 2012 → Oct 2014 | long chain fatty acids, defect in transport of | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04317508 Comparator | Nov 2019 → Feb 2020 | — | Dina Youssef Attia | Completed | No outcome recorded |
| Phase 1/2 | NCT01274247 Comparator | Feb 2011 → Jun 2012 | ankyloglossia | Tel-Aviv Sourasky Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03790540 Comparator | Dec 2018 → Mar 2019 | — | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 2 | NCT02037893 Comparator | Nov 2013 → Sep 2014 | otitis media | Currax Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01588535 Comparator | May → Aug 2012 | otitis media | Arbor Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02044341 Comparator | Dec 2013 → Mar 2014 | otitis media | Arbor Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02074007 Comparator | Dec 2013 → Jun 2014 | otitis media | Arbor Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT06165432 Comparator | Mar → Sep 2021 | — | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT03738904 Background | Oct 2018 → Aug 2022 | anus disorder | Cedars-Sinai Medical Center | Completed | Met primary |
| Phase 4 | NCT03323528 Comparator | Feb → Jul 2017 | pharyngitis | Medice Arzneimittel Pütter GmbH & Co KG | Completed | No outcome recorded |
| Phase 4 | NCT01951820 Comparator | Aug 2013 → Jun 2014 | — | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT00846690 Comparator | Jan → Mar 2009 | — | The University of Texas Health Science Center, Houston | Unknown | No outcome recorded |
| Phase 4 | NCT00716443 Comparator | Jul → Sep 2008 | — | Galderma R&D | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT00474175 Comparator | May 2007 → Dec 2010 | dental abscess | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| — | NCT06691269 Comparator | Jul 2025 → Dec 2026 expected | — | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| — | NCT06992193 Comparator | Jan → Apr 2025 | — | Ege University | Completed | No outcome recorded |
| — | NCT07082621 Comparator | Jan 2024 → Mar 2025 | mucositis | Hams Hamed Abdelrahman | Completed | No outcome recorded |
| — | NCT05861154 Comparator | Dec 2022 → Jul 2023 | — | Aliaa Hamouda | Unknown | No outcome recorded |
| — | NCT05083975 Comparator | Jul → Dec 2022 | — | Cairo University | Completed | No outcome recorded |
| — | NCT05564442 Comparator | Jun → Dec 2022 | — | Minia University | Unknown | No outcome recorded |
| — | NCT05338983 Background | May 2022 → May 2023 | — | Mansoura University | Unknown | No outcome recorded |
| — | NCT03953001 Background | Jan → Apr 2018 | — | Imam Abdulrahman Bin Faisal University | Completed | No outcome recorded |
| — | NCT03176446 Comparator | Oct 2017 → Nov 2018 | — | Universidade Estadual de Ponta Grossa | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT01860235 Comparator | Jun 2010 → Mar 2012 | — | Franciscan University Center | Completed | No outcome recorded |
Evidence & citations 35 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benzocaine | “Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray).” NCT04859738 ↗47“liposome-encapsulated 2% ropivacaine gel (RL2); 20% benzocaine gel (B20); liposomal placebo gel (LP); and placebo gel (P).” PMID 21112538 ↗ Dec 2010 “CTY-5339A is an investigational topical anesthetic spray containing 14% benzocaine/2% tetracaine in a metered canister.” PMID 30660443 ↗ Jan 2019 “the combination of benzocaine and tetracaine has a longer duration of local anesthetic activity than benzocaine alone.” NCT02908620 ↗ “topical anesthetics agents (BBC \[Benzocaine, Benzydamine, and Cetalkonium chloride\] oral spray - oracure gel)” NCT07082621 ↗ “20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection” NCT02379221 ↗ “All patients received topical 20% benzocaine gel prior to injection.” NCT06992193 ↗ “Application of topical anesthetic for 60 seconds with benzocaine” NCT03176446 ↗ “20% Benzocaine gel will be applied on the area of infiltration” NCT05338983 ↗ “Dexamethasone (included with benzocaine in local anesthesia)” NCT03738904 ↗ “20% Benzocaine gel was applied on the area of infiltration” NCT03953001 ↗ |
| Known as | Aezodent | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Americaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Anaesthesin | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Anthisan plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | AR01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02074007 ↗ |
| Known as | Baby anbesol | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Benzocaina | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Benzocaine Spray | “Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray).” NCT04859738 ↗ |
| Known as | Benzocainum | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Benzokain Sprey | “Benzokain Sprey was applied to Experiment II group before peripheral intravenous catheter application.” NCT04859738 ↗ |
| Known as | Burneze | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Children's chloraseptic | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Dequacaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Dermoplast | “This kit will contain 14 perineal ice packs, one container of 100 medicated witch-hazel pads (MAJOR® Medi-Pads), and one 2.75 oz can of 20% benzocaine with aloe spray (Dermoplast®).” NCT07401134 ↗ |
| Known as | Ethyl aminobenzoate | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Ethyl p-aminobenzoate | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Ethyl paba | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Ethyl para-amino benzoate | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Flavamed | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Lanacane | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Medilave | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Nestosyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Norcaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | NSC-41531 | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | NSC-4688 | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Opahl Topical Gel | “20% benzocaine gel (Opahl Topical Gel)” NCT05083975 ↗ |
| Known as | Orajel | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Parathesin | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Parathesine | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Subcutin | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Known as | Tyrosolven | ChEMBL registry synonym — accepted as the source's own label CHEMBL278172 ↗ |
| Action | Inhibit | “Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication.” NCT01694004 ↗ |
| Modality | Small molecule | — CHEMBL278172 ↗ |
| Route | Topical | “apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections” NCT00716443 ↗ |